Performance comparison of two whole genome amplification techniques in frame of multifactor preimplantation genetic testing by Volozonoka, Ludmila et al.
GENETICS
Performance comparison of two whole genome amplification
techniques in frame of multifactor preimplantation genetic testing
Ludmila Volozonoka1,2 & Dmitry Perminov2,3 & Liene Korņejeva2 & Baiba Alkšere2 & Natālija Novikova2,4 &
Evija Jokste Pīmane2 & Arita Blumberga2 & Inga Kempa1 & Anna Miskova5 & Linda Gailīte1 & Violeta Fodina2
Received: 6 December 2017 /Accepted: 12 April 2018 /Published online: 23 April 2018
# The Author(s) 2018
Abstract
Purpose To compare multiple displacement amplification and OmniPlex whole genome amplification technique performance
during array comparative genome hybridization (aCGH), Sanger sequencing, SNaPshot and fragment size analysis downstream
applications in frame of multifactor embryo preimplantation genetic testing.
Methods Preclinical workup included linked short tandem repeat (STR) marker selection and primer design for loci of interest. It
was followed by a family haplotyping, after which an in vitro fertilization preimplantation genetic testing (IVF-PGT) cycle was
carried out. A total of 62 embryos were retrieved from nine couples with a confirmed single gene disorder being transmitted in
their family with various inheritance traits—autosomal dominant (genes—ACTA2, HTT, KRT14), autosomal recessive (genes—
ALOX12B, TPP1, GLB1) and X-linked (genes—MTM1, DMD). Whole genome amplification (WGA) for the day 5 embryo
trophectoderm single biopsies was carried out by multiple displacement amplification (MDA) or polymerase chain reaction
(PCR)-based technology OmniPlex and was used for direct (Sanger sequencing, fragment size analysis, SNaPshot) and indirect
mutation assessment (STR marker haplotyping), and embryo aneuploidy testing by array comparative genome hybridization
(aCGH).
Results Family haplotyping revealed informative/semi-informative microsatellite markers for all clinical cases for all types of
inheritance. Indirect testing gave a persuasive conclusion for all embryos assessed, which was confirmed through direct testing.
The overall allele dropout (ADO) rate was higher for PCR-based WGA, and MDA shows a better genomic recovery scale. Five
euploid embryos were subjected to elective single embryo transfer (eSET), which resulted in four clinical pregnancies and birth of
two healthy children, which proved free of disease causative variants running in the family postnataly.
Conclusions A developed multifactor PGT protocol can be adapted and applied to virtually any genetic condition and is capable
of improving single gene disorder preimplantation genetic testing in a patient-tailored manner thus increasing pregnancy rates,
saving costs and increasing patient reliability.
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Introduction
Preimplantation genetic testing (PGT), formerly known as
PGD for monogenic disease testing or PGS for chromosome
screening, is an alternative to prenatal testing for couples being
at risk of transmitting a genetic disorder to their offspring [38].
PGT allows exclusion of affected embryos before a clinical
pregnancy has been established thus avoiding invasive prenatal
testing and elective termination of pregnancy due to prenatally
confirmed diagnosis. The material for PGT can be collected
from day 3 or day 5 of developing embryo before its transfer
to the uterus. The process initially requires controlled ovarian
hyperstimulation, oocyte retrieval and subsequent oocyte
in vitro fertilization (IVF), most commonly by intracytoplasmic
sperm injection (ICSI) followed by embryo cultivation until the
desired stage of development as well as a biopsy procedure [1].
Depending on a protocol, PGT can be done with or without
embryo vitrification for the time of testing. Only embryos
proved free of the disease-causing variant under consideration
are subsequently transferred into the uterine cavity.
The success of the whole procedure depends mostly on
competence and appropriate collaboration of the multidisci-
pl inary team consis t ing of a cl inical genet ic is t ,
reproductologist, gynaecologist, embryologist and molecular
geneticist, and is achieved through safety and accuracy, im-
proving genetic and reproductive medicine practices [6]. PGT
is currently performed for single gene disorders (SGDs), late-
onset disorders with genetic predisposition, chromosomal dis-
orders, including aneuploidy and structural rearrangements,
and HLA (human leukocyte antigen) typing to improve the
access to HLA-matched stem cell transplantation [28].
The history of PGT goes back to 1989 when A. Handyside
performed first preimplantation genetic diagnostic (PGD)
cases detecting a Y chromosome-specific region with PCR
in case of X-linked adrenoleukodystrophy and X-linked men-
tal retardation [13]. Now, defining embryo gender is known as
sexing and can complement to genetic testing of monogenic
disorders linked to the sex chromosomes.
With time, PGT underwent significant methodological and
approach changes, starting from polar body testing and blas-
tomere analysis and now adapting trophectoderm biopsy with
subsequent blastocyst freezing [26]. The analysis of more than
a single cell leads to a more robust downstream molecular
investigation, which sets among the reasons blastocyst stage
biopsy strategy [5]. Molecular genetic testing developed from
single loci directs PCR till sophisticated single cell whole
genome amplification [9]. Embryo haplotyping offers a more
generic approach to preimplantation diagnosis, and is espe-
cially useful for diseases with a wide spectrum of causative
variants, such as cystic fibrosis and Duchenne muscular dys-
trophy [26].
Despite technological improvements, development of PGT
protocols is challenging and prone to amplification failure,
DNA contamination and ADO (allele dropout)—a phenome-
non common to all single cell-based PCR tests, thus affecting
the reliability of the test. ADO can be defined as amplification
failure affecting only one of the parental alleles. ADO’s inci-
dence varies, but in extreme cases has affected 20% of ampli-
fications and in the past has led to several misdiagnoses [3].
The causes of misdiagnosis include swap of samples, transfer
of the wrong embryo, maternal or paternal contamination,
ADO, use of inappropriate probes or primers, probe or primer
failure and chromosomal mosaicism [15].
ADO rates should be as low as possible, preferably less
than 10%. Higher ADO rates can be tolerated when dealing
with WGA-based protocols and autosomal recessive diseases
compared to autosomal dominant or compound heterozygous
cases. However, in such cases an increased number of linked
markers have to be used [15].
Choosing the WGA type is also challenging due to difficul-
ties in interpretation of downstream applications like short tan-
dem repeat (STR) marker sizing with fluorescent polymerase
chain reaction (fPCR) or array comparative genomic hybridi-
zation [25]. At the moment, several WGA technologies exist
[40], for example, PCR-based approaches like degenerate oli-
gonucleotide primer (DOP) [31] or primer extension (PEP)
PCR technology [39]. Leading positions are taken by
OmniPlex linear WGA [4, 33] technology developed by
Rubicon Genomics and multiple displacement isothermal syn-
thesis by a Phi29 polymerase approach (Alan H. [14]). Both of
them have advantages and disadvantages. The use of TaqDNA
polymerase in PCR-based approaches limits the fragment
lengths to 3 kb. The Phi29 polymerase used forMDAgenerates
DNA fragments up to 100 kb and has a 3′→ 5′ exonuclease
proofreading activity. Often, it is not clear which technology
could be prioritized in custom-designed protocols [40].
Better PGT results are now achieved through combining
direct and indirect testing, using platforms like Karyomapping
[12] for genome-wide linkage analysis or turning to next gen-
eration sequencing (NGS) protocols (Francesco [10]).
However, current studies still highlight clinically important
limitations in the reliability of the technologies; for example,
using Karyomapping, ∼ 14% of embryos are expected to re-
main without a conclusive result [19]. NGS has potential pow-
er to increase throughput and evaluate multiple genetic loci in
parallel, but it is also well known for sequencing artefacts,
which may complicate its application to PGD [32]. Also, costs
are still quite high especially for limited sample amounts.
Regardless of the fact that PGT is recognized for its bene-
fits, it is still relatively unregulated and lacks standardization
compared with other forms of diagnostic testing [15]. This is
partially because PGD lies at the intersection of two technol-
ogies with a confusing regulatory status: assisted reproduction
and genetic testing [8]. It is admitted that a robust PGT test
should be able not only to distinguish between a normal and
affected embryo, but also to highlight all the unexpected
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events that may happen during meiosis, fertilization or PGD
experimental procedure, and thus it should detect recombina-
tion, monosomy or trisomy and therefore diagnose abnormal
embryos and detect ADO and contamination [18]. In case of
adverse misdiagnosis, lessons can be very painful to patients
and staff [16, 36].
Despite numerous advances, assisted reproductive technol-
ogy (ART) live birth rates are still low ranging from 27 to
55%, depending on the patient age group and methodology
used [6]. Another step in reaching considerably good results
for SGD-PGT is embryo aneuploidy exclusion since it is well
known that preimplantation human embryos are prone to
chromosome instability [34] and high aneuploidy rates [18,
35]. Early results show that combined PGD and PGS increase
patient chance for a healthy childbirth [20, 30].
Taking into account the aforementioned information, the
aim of our study was to develop an individualized effective
and robust multifactor embryo testing protocol and show a
performance comparison of two WGA techniques in four dif-
ferent downstream applications—STR sizing, Sanger se-
quencing, aCGH and SNaPshot technology. We present our
PGT experience for single gene diseases of autosomal domi-
nant (genes: ACTA2, HTT, KRT14), autosomal recessive
(genes: ALOX12B, TPP1, GLB1) and X-linked (genes:
MTM1, DMD) types of inheritance.
Materials and methods
Cases processed
Nine couples (Table 1) with confirmed particular single gene
disease being transmitted in their family underwent counsel-
ling regarding PGT procedure, ovarian stimulation, oocyte
aspiration and IVF at the single centre of infertility and repro-
ductive genetics where all biological material samples were
collected and processed.
Compliance with ethical standards
The study is in accordance with the Declaration of Helsinki
ethical principles. All patients considered for PGT underwent
genetic counselling. Procedures and manipulations needed for
embryo genetic testing were explained in detail, and signed
informed consent was obtained. The study protocol was ap-
proved by a local ethical community. PGD is recognized as
Ban established procedure with specific and expanding appli-
cations for standard clinical practice^ by the Practice
Committee of the American Society for Reproductive
Medicine and the Practice Committee of the Society for
Assisted Reproductive Technology (2006). No research was
conducted on the embryos. All genetic conditions for which
PGT was performed are approved by HFEA (Human
Fertilization and Embryology Act) as suitable for genetic test-
ing in preimplantation embryos.
Preclinical workup
Before processing a clinical case, a workup was carried
out to prepare each PGT case. Linked microsatellites ad-
jacent to the gene of interest (within ~ 2 Mb upstream and
downstream from the mutation locus) were located
through a University of California Santa Cruz (UCSC)
genome browser (https://genome-preview.ucsc.edu/index.
html). For all loci (disease-causative variant site and
STR markers), semi-nested primers for two round multi-
plex fPCRs (inner primer fluorescently tagged with 6-
FAM or HEX fluorophores at the 5′ end) were designed
using BPrimer-BLAST^ to ensure specificity [37] follow-
ing good practice guidelines [16]. Primer dimer and
primer-amplicon secondary structure formation was
checked using an OligoAnalyzer 3.1 online software tool
[23].
DNA obtained from the peripheral venous blood of couples
seeking PGD and other family members (usually three to five
individuals) was isolated using a standard procedure (Qiagen).
Family haplotypes flanking locus of interest were assessed.
STR marker informativeness was evaluated as follows: fully
informative (three or four different paternal and maternal al-
leles, depending on the type of inheritance, both disease-
causative and healthy, are distinguishable), semi-informative
(one or two different alleles can be distinguished and assigned
to the normal or disease-causative haplotype) and not infor-
mative (origin of the allele or the assignment to the haplotype
cannot be distinguished) [15].
When PCR linkage analysis was performed for a family, 6–
13 (8.1 ± 2.5) informative or semi-informative STR markers
(Table 3) were included in the following PGT cycle for em-
bryo analysis. The STRmarker informativeness rate was 53%.
For autosomal recessive disorders, significantly higher STR
amounts contribute to an overall assay informativeness rate:
13/15 and 10/15 compared to autosomal dominant or X-linked
conditions i.e. 7/17 and 6/13 informative markers (please refer
to Table 3). Disease-causative variant confirmation in family
members was carried out via Sanger sequencing for single
nucleotide variation (SNV) or by fragment size analysis for
trinucleotide repeat expansion.
IVF and embryo biopsy
Oocyte cumulus complexes (COC) were retrieved by a needle
transvaginal aspiration procedure. All oocytes were fertilized
through intracytoplasmic sperm injection (ICSI) and placed in
a time-lapse incubator (EmbryoScope, Vitrolife, UK).
Fertilization was acknowledged as successful if two pronuclei
(PN) were observed on the next day after ICSI. Embryos were
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incubated until the day-5 blastocyst stage. The embryo devel-
opment rate was scored based on a time-lapse system moni-
toring algorithm [22]. Through natural selection, the average
5th-day survival rate was 70%. In total, 62 patient embryos
were subjected to PGT (Table 2). Embryo biopsies were made
using a laser-assisted micromanipulator (Narishige, Japan).
From each embryo, one to eight trophectodermal cells were
taken from the outer layer of the blastocyst, and all embryos
survived the biopsy procedure. Biopsied cells were washed in
1× phosphate-buffered saline (PBS) buffer (Cell Signaling
Technologies, USA) drops to reduce the risk of contamination
and subsequently placed in 0.2-ml tubes within 2.0 μl of 1%
polyvinylpyrrolidone (FertiPro, Belgium) 1× PBS buffer and
frozen immediately, and each blastocyst culture media con-
tamination control was collected as well. Biopsied embryos
were vitrified.
Performance of clinical cases
As a first step for all embryo biopsies, WGAwas carried out.
For one part of the embryos (n = 39), WGA was done by
MDA technology (SureMDA, Illumina, USA); the rest (n =
34) were carried out by OmniPlex linear WGA technology
(SurePlex, Illumina, USA) (Table 4). Aliquots of the WGA
product from each sample were used to carry out different
downstream tests.
Embryo haplogroup analysis was carried out assessing in-
formative markers found in a linkage step. Two round (nested)
PCR conditions were used: 8.2 μl of Type-it Master Mix
(Qiagen, USA), 0.32 μl of 0.2 μM forward (outer-forward
primer for the first stage of hemi-nested PCR and inner-
forward primer for the second-round PCR stage; synthesized
by Bioneer, China) and 0.2 μM reverse primers (similar for
Table 1 Processed PGT cases description












HTT AD CAG repeat
expansion
34 29 Carrier female partner, her












KRT14 AD c.374G>A 30 31 Affected male partner,
healthy female partner,
their affected child
TPP1-case Classic late infantile
neuronal ceroid
lipofuscinosis










35 32 Carrier female and male
partners, their affected
child
DMD-case 1 Duchenne muscular
dystrophy
(family 1)
DMD X-linked Duplication of
exons 45–47
and 51–52
39 35 Carrier female partner,
healthy male partner, their
affected son and carrier
daughter
DMD-case 2 Duchenne muscular
dystrophy
(family 2)






MTM1 X-linked c.70C>T 34 35 Carrier female partner, her
healthy sister, her carrier
mother and healthy father,
healthy male partner, their
affected child
GLB1-case GM1 gangliosidosis GLB1 AR c.1768C>T;
c.833delG
36 38 Carrier female and male
partners, their affected
child
Average 34.4 ± 2.8 32.8 ± 2.5
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both PCR steps), 6.8 μl of ddH2O and 0.62 μl of WGA prod-
uct. Cycling conditions are as follows: initial denaturation for
5 min at 95 °C, followed by 28 cycles (first-round PCR) or
22 cycles (second-round PCR) for 30 s at 95 °C, 1 min and
30 s at 60 °C and 30 s at 72 °C and a final extension for 10min
at 72 °C. Amplified products were run on agarose gel electro-
phoresis to detect the PCR product. Amplicon detection was
performed by capillary electrophoresis (ABI Prism 3500
DNA Analyzer; Applied Biosystems, USA). Allele sizing
was carried out using GeneMapper v.4.0 software (Applied
Biosystems).
Direct mutation analysis for SNVs was carried out by a
standard Sanger sequencing protocol [27] or SNaPshot tech-
nology (Applied Biosystems, USA). HTT gene (OMIM#
613004) CAG repeat expansion (RCV000030659, HGVS no-
menclature—NM_002111.6(HTT):c.53_55[(41_?)]
(p.Gln40(41_?)) was detected by capillary electrophoresis
using the same protocol as for STR marker loci amplification.
Embryo chromosome analysis was performed following
the manufacturer’s (24sure, Illumina, USA) protocol for
aCGH, shortly: the WGA product was fluorescently labelled
by a nick translation method with Cy3 and Cy5 fluorophores,
the reference DNAwas hybridized on BAC array microchips,
and microchip glasses were washed and scanned with an
InnoScan (Innopsys, France) scanner. Tiff images were
imported into BlueFuse Multi V4.0 software (standard set-
tings), and the resulting copy number karyotypes were
assessed. The givenmethodology detects unbalanced chromo-
somal material changes and polyploidy if sex chromosomes
are represented by at least one X and Y chromosome.
ADO rates were calculated by dividing homozygous geno-
type events when a heterozygous genotype was expected for
the number of all expected heterozygous loci. In order to ac-
cess whether ADO rates are affected by downstream applica-
tion, STR ADO calculations were assessed per individual case
as well as per each WGA type. For Sanger sequencing and
SNaPshot technologies, ADO rates we assessed separately for
each technology (please refer to Table 4). ADOwas counted if
an alternative allele was completely absent or was hardly dis-
tinguishable from the artefact (partial ADO).
Results
Embryo PGT analysis
For all 62 patient embryo biopsies, WGA amplification per-
formed either by SureMDA or SurePlex kit (Table 4) was
successful and eventually had a conclusive result (Table 3,
Fig. 1 and Supplementary Figs. 1–7 for the pedigrees).
Additional 11 OmniPlex samples were donated for research.
In case of MTM1 gene testing after two stimulation cycles,
none of the oocytes underwent successful fertilization. The
KRT14-case family underwent only linkage analysis and
now are preparing for follicular stimulation.
The portion of each embryo WGA product was used for
haplotyping informative or semi-informativemarkers detected
by initial family linkage analysis. The overall STR ADO rate
was 4.74% (Table 4) exceeding the 5% cut-off only in DMD-
case 1, where the WGA product generated by OmniPlex had
lower quality due to long-time storage and repeated freeze-
thaw events. aCGH for this DMD-case 1 was performed first-
ly when haplotyping was unavailable (please refer to Table 3
and corresponding pedigree).
In one case, maternal uniparental disomy of the tested locus
was observed (GLB1-case e4; please see the pedigree). In
three embryos, crossover events were detected through
haplotyping. TPP1-case e5 analysis was encumbered due to
close proximity of the crossover site to the mutation locus
making it impossible to exclude direct testing ADO and pos-
sible heterozygous embryo genotypes. In all cases, crossover
occurred next to the mutation locus, which complicates par-
ticular embryo analysis, but direct mutation analysis
complemented and clarified haplotyping results.
Direct mutation testing was done for all cases processed
except for DMD-case 1. For HTT gene’s CAG, triplet repeat
sizing was performed by fPCR. Sanger sequencing and/or
SNaPshot analysis was applied for SNVanalysis, and no mis-
matches were identified between direct and indirect tests. In
all cases, at least one embryo free of tested disease-causative
variant was detected.
In most cases, a portion of the WGA product from
mutation-free embryos was subjected to aCGH analysis to
exclude chromosomal aneuploidies. For the HTT-case and
ALOX12B-case, only some of the tested disease-causative
variant-free embryos were subjected to chromosome analysis
due to financial reasons, in these cases only embryos, which
showed best development scores according to the
EmbryoScope algorithm, which were taken for analysis. In
all cases, at least one euploid embryo was available
(Table 3). Only embryos free of disease-causative variants
were assessed, and euploids were rated as transferable. All
embryos subjected to the embryo transfer procedure
underwent thawing successfully.
Elective single euploid embryo transfers (eSET) in two
cases resulted in healthy newborn babies. Transfer of TPP1
and ACTA2 variant-free embryos resulted in progressing clin-
ical pregnancies. For the first Duchene muscular dystrophy
case initially, only sexing for PGD by aCGH was performed
and 46,XX embryo transfer resulted in a healthy carrier baby
birth; only later were all their embryos haplotyped, and a sec-
ond eSET resulted in failed embryo implantation. Another
DMD family prepared for the eSET procedure. Three babies
born after PGT underwent postnatal mutation assessment, and
preimplantation genetic testing results were confirmed. The
overall pregnancy rate is 83%.
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Comparison of two different WGA techniques
To compare two WGA methods, one part of the biopsies was
subjected toMDA technique and the rest were amplified by an
OmniPlex reagent kit (please refer to Table 4 for the detailed
view). A typical MDA product pattern (smear) on 1.5% aga-
rose gel is observable as bands at about 6–12 kb. On the
contrary, PCR-based WGA results in much shorter products
visible as a smear appearing between 1 kb and 100 bp with
most prominent bands at around 500 pb (Supplementary
Fig. 9). Both types of WGAwere subjected to all four down-
stream applications—Sanger sequencing, STR amplification,
SNaPshot and aCGH (Table 4).
Our results show that both WGA methodologies result in
partial ADO when Sanger sequencing is performed (Fig. 2).
Poor amplification of disease-causative alleles can be distin-
guishable as a low-level electropherogram in otherwise clear
profiles. One TPP1-case sample resulted in complete disease
causative allele ADO even despite a hemi-nested amplifica-
tion approach. ADO rates (partial ADO, since only one
Fig. 1 Pedigrees. DMD-case 2 and ACTA2-case pedigrees showing
family members participating in haplotype establishment and all
embryos analysed. Red bars represent disease variant loci. Black
crosses indicate recombination events. In blue, variant-free haplotypes
are indicated. In red, variant haplotypes are indicated. ADO—allelic
dropout
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complete ADO was detected) for Sanger sequencing are
higher in the case of OmniPlex compared to MDA (10 and
21.4% accordingly).
We were also interested in comparing both WGA when
subjected to SNaPshot genotyping technology (Fig. 3,
Supplementary Fig. 8). The MDA product resulted in compa-
rable results to haplotyping and Sanger sequencing, and all the
genotypes matched, with an ADO rate for MDA SNaPshot
5.5%, whereas the OmniPlex product repeatedly did not pro-
duce any reliable profiles or failed to amplify completely (not
shown) in more than 60% of samples.
Due to the nature of twoWGA types, they arise in different
downstream STR amplification product sizing patterns per-
formed on capillary electrophoresis. Much prominent false
peaks arise due to polymerase slippage during OmniPlex am-
plification and subsequent preferential amplification of partic-
ular PCR products, making it possible to distinguish true al-
leles from the false ones only by comparing them to parental
genomic DNA samples run in parallel (Figs. 4 and 5).
Rubicon Genomics technology has been proven to perform
well in single-cell aCGH amplifications resulting in clear flat
profiles, which is true in our study as well. Whereas the MDA
aCGH profile results in increased noise compared to
OmniPlex WGA (Fig. 6); therefore, chromosome microarray
analysis in such case is possible only for the whole chromo-
somes, but not the partial copy number variations.
Discussion
It is widely recognized that development of preimplantation
genetic testing protocols is time consuming, costly and labo-
rious, because of a wide spectrum of technical complications
and biology-driven obstacles [3, 36]. It is essential to remem-
ber that the interpretation of results may influence not only
particular family wealth but also in the long term even the
well-being of the whole society, since PGT is a potential tool
to cease out at least some genetic conditions.
Performance and outcome requirements for our approach
were subjected to the following measures: possibility to com-
bine several technologies in order to distinguish a normal em-
bryo from a carrier and an affected one, to distinguish possible
contamination and loci/allelic dropout events and to perform
embryo chromosome screening. It was relevant to get a con-
clusion on all embryos subjected to biopsy and avoid any
additional embryo manipulations like repeated thawing and
rebiopsy. Such a wide spectrum of requirements was set care-
fully taking into consideration all the previous historical ob-
stacles of PGT. We aimed first to meet the highest safety
standards and secondly to prioritize a purpose of achieving
the desired pregnancy in a personalized and customized man-
ner saving patient time and expenses, which was shown
through a comprehensive comparison of two different WGA
techniques.
In general, obtaining micrograms of DNA through
WGA of day-5 embryo biopsies allowed us to perform
embryo haplotype analysis, aneuploidy screening by
aCGH and direct mutation testing through SNaPshot,
Sanger sequencing or fragment size analysis. As shown
before, direct variant locus testing boldly complements
the indirect one [18, 21], since crossover events cannot
be completely ruled out and ignored [11] especially in the
case of ADO, which was also true in our cohort. We de-
signed hemi-nested primers for all assessed loci following
PGDIS guidelines for good practice in PGD [16, 24]. We
conclude that having as much as possible a number of
semi-informative and/or informative linked markers within
reasonable distance upstream and downstream from a gene
is the best way to minimize the risk of misdiagnosis or no
conclusive diagnosis for a particular embryo.
To our knowledge, our work is the first attempt in evaluat-
ing Picoplex andMDA amplifier performance across different
downstream applications in frame of embryo preimplantation
genetic testing. Provided figures give insight in understanding
the applicability of bothWGAmethodologies to different mo-
lecular techniques and assist in choosing one when customiz-
ing PGT depending on the mutation type and technical equip-
ment of the laboratory.
Currently, single-/few-cell WGA might be done with a
wide array of amplification strategies [2]. We conclude that
methodology choice depends on multiple factors like desired
downstream application techniques as well as embryo
amount. STR analysis efficacy including possible ADO event
detection depends mostly on particular genomic region nucle-
otide composition and can be improved through PCR reaction
condition optimization. TheMDAWGA product compared to
OmniPlex produces more heavy DNA strings, thus exhibiting
properties closer to genomic DNA, and therefore, electrophe-
rograms are much clearer. Our results are consistent with other
group findings that the per base error rate for MDA is at least
two times lower compared to PCR-based approaches as
shown for Sanger sequencing and SNaPshot applications. In
general, MDA shows better genome recovery sensitivity as
also concluded before [17] while allowing for a more conve-
nient genotyping. However, MDA results in significant am-
plification bias [7], which contributed to the observed high
aCGH noise levels. For full-fledged analysis, we recommend
usage of both WGA techniques dividing the embryo cohort if
Fig. 2 Sanger sequencing profiles of different WGA technologies.
ACTA2-case and DMD-case 2 are shown. PGD father (first upper
panel) and PGD mother (third panel) represent locus controls performed
on gDNA. Haplotype analysis of both given embryos corresponds to
heterozygous genotype (confirmed by STR haplotyping). Red arrows
mark partial loss (partial allelic dropout, ADO) of disease-causing allele
in analysed embryos, which are only detectable as weak background
profiles similar to noise
J Assist Reprod Genet (2018) 35:1457–1472 1467
1468 J Assist Reprod Genet (2018) 35:1457–1472
the embryo amount is big enough. If the number of
(semi-)informative markers is low, it is favourable to use the
MDA technique since this will result in more robust SGD
locus analysis. If STR marker informativenes is high enough,
ADO will not drastically affect the result when detecting pos-
sible crossover events, and one might consider using
OmniPlex since it gives more reliable aCGH profiles.
It is known that embryo aneuploidy and implantation po-
tential are highly correlated with biopsy stage. Cleavage-stage
embryo blastomere biopsy still represents the most commonly
used method in Europe, although this approach has been
shown to have a negative impact on embryo viability and
implantation rates [5, 29]. Therefore, day 5 biopsy is highly
favourable. In our study, trophectoderm biopsy performance
was additionally complemented by usage of a time-lapse em-
bryo imaging system, which not only aims at biopsy timing,
but also can give a clue for the best choice of developing
embryo for transfer through assessment of embryo rating by
a time-lapse system algorithm when multiple embryos are
SGD free and euploid.
Our experience with preimplantation testing began with a
lot of goals and aims that were expected from a clinical and
molecular point of view. We tried to set up a diagnostic algo-
rithm that would suit every case and be foolproof. It became
apparent already with our first cases that the approach should
be more patient tailored than universal and more based on
close communication between patients, clinical geneticists,
reproductologists, embryologists and molecular geneticists
than on pure data analysis. Proper genetic counselling before
planning a PGT case is crucial as the patient has to be
acquainted to any potential pitfalls to give a fully informed
consent for testing. The final strategy of molecular testing
should better be made after taking into consideration available
embryo amount and morphology, type of disorder and family
specifics and preferences. Although the main goal during
monogenic disease preimplantation testing would always be
disease-causative variant-free embryo selection, we found it
expedient to use aneuploidy testing besides morphological
embryo evaluation to determine the embryo most suitable
for eSET thus increasing the chance for successful embryo
implantation and development saving extra efforts and costs.
The final result will always depend on a lot of different fac-
tors—even after all embryo testing is done, there is a possibil-
ity of failed implantation due to maternal age factor, endome-
trial receptivity problems and many more—this is why a mul-
tidisciplinary approach is a key to success for each family and
thus the community altogether.
Fig. 4 STR haplotyping analysis. Two STR marker analysis shown for
ACTA2-case (left panel) and DMD-case 2 (right panel). Green peaks
indicate true paternal or maternal alleles. It is visible that in the case of
the OmniPlex amplifier (e8), higher peaks are of artificial nature arising
due to polymerase slippage during WGA and STR amplification
reactions with subsequent preferential amplification of wrong-size allele
Fig. 3 Comparison of STR sizing (A) and SNaPshot (B). Results shown
for DMD-case 2 variant locus (DMD c.6420del). Whole genome
amplification performed by multiple displacement amplification (MDA)
technique for three embryos shown (e10, e12, e15). Profiles completely
match between two technologies, and partial allelic dropout is visible on
both profiles for the heterozygous embryo (e12). PGDmother (first upper
panel) shows locus control performed on gDNA
J Assist Reprod Genet (2018) 35:1457–1472 1469
Fig. 6 Comparison of two WGA techniques in downstream aCGH analysis
Fig. 5 Comparison of two WGA techniques in downstream DXS8049 STR marker sizing. During STR amplification, the OmniPlex product produces
much more stutter peaks (e3, e7) compared to the MDA product (e13, e17). Green peaks indicate true inherited alleles
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Conclusions
Single blastocyst biopsy whole genome amplification ensures
possibility of multifactor preimplantation genetic testing with-
out compromising embryo viability and in general chance of
achieving a healthy pregnancy. A semi-nested direct and indi-
rect testing system minimizes embryo misdiagnosis risk due
to allelic dropout, nonspecific amplification or contamination.
24-Chromosome aneuploidy screening when performed con-
currently with single gene disorder preimplantation embryo
testing provides valuable information for embryo selection
excluding leading failed embryo implantation cause and nota-
bly improving single embryo transfer rates thus saving time
and money leading to higher pregnancy rates. A developed
protocol can be further applied to customize PGT protocols
for families seeking alternatives for prenatal testing.
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